Daunted by the prospect of a lengthy safety review, Mountain View, CA-based Vivus is giving up on its program for an experimental testosterone therapy for women. The developer says it is shelving the Luramist program and returning the rights to a subsidiary of Acrux. "The decision to terminate the agreement was made in view of the significant long-term safety requirements for the approval of testosterone products in women," stated Peter Tam, president of Vivus, in a prepared statement. "We believe it is in our shareholders' best interests to pursue other therapeutic candidates." Tam plans to focus the company on its two leading therapies: Qnexa for obesity and avanafil for erectile dysfunction.
***
Set back for Acrux or an opportunity to renegotiate the female equivilent of Axiron in light of the massive deal?
Seems a waste of time for Acrux to have to now find a new party - hopefully Lilly will be interested. I wonder if there are any details as to contractual relief for this?
Add to My Watchlist
What is My Watchlist?
